Brooks Laboratories Ltd (NSE: BROOKS) is a pharmaceutical company based in India. The company offers a range of products that include dry powder injections, liquid injections, carbapenem dry power injectables, tablets, and oral suspensions. These products are used in different therapeutic segments, such as anti-bacterial, antibiotics, anti-gastric, anti-malarial, and life-saving drugs. The company’s product portfolio is diverse and caters to a wide range of medical needs, allowing it to serve a large customer base. By offering products in different forms and therapeutic segments, Brooks Laboratories can appeal to a broad range of healthcare professionals and patients.
In December 2022, Brooks Laboratories Ltd reported a total income of Rs. 15.30 crore, a decrease of 15.49% compared to the same period in the previous year. The total expenses during this period were Rs. 23.85 crore, which is a decrease of 0.27% compared to the same period in the previous year. The company reported an EBIT (earnings before interest and taxes) of -Rs. 8.55 crore in December 2022. This means the company incurred a loss before considering the impact of interest and taxes. There is no growth rate mentioned for EBIT in the given data. The net profit after tax (PAT) for the company was -Rs. 9.48 crore in December 2022, indicating a loss. The company had reported a PAT of -Rs. 7.40 crore in the same period the previous year.
The EBIT margin in December 2022 was -67.78%, indicating that the company’s operating expenses exceeded its operating income during the period. The net profit margin was -61.59%, indicating that the company incurred a net loss. The basic earnings per share (EPS) for the company in December 2022 was -Rs. 2.03. This means that for every share of the company, the loss per share was Rs. 2.03 in December 2022.